Trial · NCT05049278
Effects of Vasopressor on the Graft Blood Flow in TRAM
NCT05049278, Not applicable, Completed, Seoul National University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Vasopressor on the Graft Blood Flow in TRAM. Trials, record NCT05049278. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05049278
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Vasopressor on the Graft Blood Flow in TRAM
- NCT number
- NCT05049278
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Seoul National University Hospital
- Conditions
- Blood Flow, Anastomotic Failure of Flap, Flap Necrosis, Flap Ischemia
- Interventions
- Norepinephrine, Phenylephrine
- First posted
- 2021-09-20
- Last updated
- 2023-05-03
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Graft mean blood flow measured using transit time flowmetry | Intraoperative period | Mean blood flow (in mL/min) of the graft vessel that was measured using transit time flowmetry |
| Primary | Pulsatility of graft vessel measured using transit time flowmetry | Intraoperative period | Pulsatility of graft vessel, which is presented as pulsatility index in unitless, that was measured using transit time flowmetry |
| Primary | Diastolic filling of the graft vessel measured using transit time flowmetry | Intraoperative period | Diastolic filling (in percentage) of the graft vessel that was measured using transit time flowmetry |
| Secondary | Graft failure rate in patients received each vasopressor during surgery | Within seven days after surgery | The rate of graft failure in patients received each vasopressor during surgery |
| Secondary | Capillary filling time in patients received each vasopressor during surgery | Within seven days after surgery | Capillary filling time, which was measured by time to refill the capillary after compression, to evaluate the viability of the flap in patients received each vasopressor during surgery |
| Secondary | Skin necrosis rate in patients received each vasopressor during surgery | Within seven days after surgery | The rate of skin necrosis, which is evaluated by any changes in skin color by description of the color of the skin by clinicians, to evaluate the viability of the graft in patients received each vasopressor during surgery |
| Secondary | Rate of vascular thrombosis in patients received each vasopressor during surgery | Within seven days after surgery | The rate of arterial or venous complication by measure of skin color change or decrease in doppler flow or capillary refill to evaluate the viability of the graft in patients received each vasopressor during surgery |
| Secondary | Rate of wound infection or any wound problem in patients received each vasopressor during surgery | Within seven days after surgery | The rate of any wound complication including infection to evaluate wound complication after surgery in patients each vasopressor during surgery |
| Secondary | Amount of transfusion in patients received each vasopressor during surgery | Within seven days after surgery | Amount of transfusion to evaluate clinical outcomes in patients received each vasopressor during surgery |
| Secondary | Total amount of remifentanil infused during surgery in patients received each vasopressor | intraoperative period | The total amount of remifentanil infused during surgery to evaluate clinical outcomes and perioperative variables in patients received each vasopressor during surgery |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05049278
GET https://conductscience.org/api/trials/v1/NCT05049278/registered